Literature DB >> 11106196

Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma.

C Severien1, A Artlich, S Jonas, G Becher.   

Abstract

Measurement of leukotriene E4 (LTE4) in urine is a noninvasive method for assessing changes in the rate of total body cysteinyl leukotriene production. Eosinophil protein X (EPX) has been used to assess eosinophil activity and monitor inflammation in bronchial asthma. The aim of the study was to look for differences in urinary LTE4 and EPX concentrations between children with stable atopic asthma and healthy controls and to compare asthmatic children with different disease severity. In addition the relationship was evaluated between urinary LTE4 and EPX levels and lung function. LTE4 was also measured (enzyme immunoassay) together with EPX (radioimmunoassay) in urine and lung function tests were carried out in children with mild asthma (steroid-naive) (n=49), moderate to severe asthma (using inhaled steroids) (n=31) and healthy control subjects (n=28). Urinary leukotriene E4 (LTE4) was significantly higher in children with asthma than in controls (median [25-75 percentile] 238.5 (126.5-375.7) SD 191.8 versus 189 (51-253.2) SD 131.7 pg.mg(-1) creatinine; p=0.021). Urinary EPX was also significantly increased in asthmatic children compared with controls (85.5 [64-131.5] SD 76.2 versus 48.5 [43.2-90] 112.1 microg x mmol(-1) creatinine; p=0.006). There were no differences in urinary LTE4 and EPX between the group of mild and the group of moderate to severe asthmatic children. There were significant associations between the urinary LTE4 and intrathoracic gas volume (ITGV), residual volume (RV), forced expiratory volume in one second (FEV1), forced expiratory capacity (FVC) and maximum expiratory flow rate at 25% of vital capacity (MEF25). Urinary EPX was only correlated with maximum expiratory flow rate at 75% of vital capacity (MEF75). Thus measurement of urinary LTE4 may predict the degree of airflow obstruction in asthmatic children. Urinary LTE4 and EPX are useful markers of airway inflammation and can be helpful in guiding asthma management. There was no correlation between LTE4 and EPX levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106196     DOI: 10.1034/j.1399-3003.2000.16d03.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

1.  Fish Oil Supplementation in Overweight/Obese Patients with Uncontrolled Asthma. A Randomized Trial.

Authors:  Jason E Lang; Edward B Mougey; Md Jobayer Hossain; Floyd Livingston; P Babu Balagopal; Scott Langdon; John J Lima
Journal:  Ann Am Thorac Soc       Date:  2019-05

Review 2.  G-protein-coupled receptors and asthma endophenotypes: the cysteinyl leukotriene system in perspective.

Authors:  Miles D Thompson; Jun Takasaki; Valérie Capra; G Enrico Rovati; Kathy A Siminovitch; W McIntyre Burnham; Thomas J Hudson; Yohan Bossé; David E C Cole
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

3.  Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation.

Authors:  S A Green; M-P Malice; W Tanaka; C A Tozzi; T F Reiss
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

4.  Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma.

Authors:  Nathan Rabinovitch; David T Mauger; Nichole Reisdorph; Ronina Covar; Jonathan Malka; Robert F Lemanske; Wayne J Morgan; Theresa W Guilbert; Robert S Zeiger; Leonard B Bacharier; Stanley J Szefler
Journal:  J Allergy Clin Immunol       Date:  2013-09-29       Impact factor: 10.793

5.  Urinary LTE4 levels as a diagnostic marker for IgE-mediated asthma in preschool children: a birth cohort study.

Authors:  Chih-Yung Chiu; Ming-Han Tsai; Tsung-Chieh Yao; Yu-Ling Tu; Man-Chin Hua; Kuo-Wei Yeh; Jing-Long Huang
Journal:  PLoS One       Date:  2014-12-18       Impact factor: 3.240

Review 6.  Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies.

Authors:  Miles D Thompson; Valerie Capra; Mark T Clunes; G E Rovati; Jana Stankova; Mary C Maj; David L Duffy
Journal:  Front Pharmacol       Date:  2016-12-01       Impact factor: 5.810

7.  Urinary eosinophil protein X in childhood asthma: relation with changes in disease control and eosinophilic airway inflammation.

Authors:  Marianne Nuijsink; Wim C J Hop; Peter J Sterk; Eric J Duiverman; Johan C De Jongste
Journal:  Mediators Inflamm       Date:  2013-01-15       Impact factor: 4.711

8.  Urinary eosinophil protein X in children with atopic asthma.

Authors:  M Nuijsink; W C J Hop; P J Sterk; E J Duiverman; P S Hiemstra; J C de Jongste
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

Review 9.  Eosinophil protein X and childhood asthma: A systematic review and meta-analysis.

Authors:  Hillary Klonoff-Cohen; Mounika Polavarapu
Journal:  Immun Inflamm Dis       Date:  2016-04-01

10.  A Double-Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Korean Children.

Authors:  You Hoon Jeon; Taek Ki Min; Hyeon Jong Yang; Bok Yang Pyun
Journal:  Allergy Asthma Immunol Res       Date:  2016-07       Impact factor: 5.764

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.